Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technol
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... QC , March 1, 2015 /CNW Telbec/ -   ... Laval and known under the « ... results for the second quarter Ended on December 31, ... in Canadian currency. Revenues for the ... December 31, 2014 totaled $ 4 095 112 decreasing by 8,8 % ...
(Date:2/27/2015)... 2015 Pharmaceutical and biotech marketers are often ... the same indication. This can be a complex balancing ... one of their brands from gaining market share at ... research by benchmarking firm, Best Practices, LLC, 75% of ... than together as part of a franchise. Marketers have ...
(Date:2/27/2015)... 2015  Acsis Inc., the market leader for supply ... that John DiPalo , Acsis, Chief Strategy Officer, ... Chain Executive 2015 Provider Pro to Know. The ... to help prepare their companies, and customers, supply chains ... year,s list of Provider Pros to Know is featured ...
Breaking Medicine Technology:Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... Inc. (Nasdaq: REGN ) will webcast its ... 15, 2011.  The presentation is scheduled for 2:10 p.m. ... Company,s web site, www.regeneron.com , on the Investor ... be available after the live webcast through March 17, ...
... Pervasis Therapeutics announced today that the U.S. Food and ... for Vascugel® for the prevention of hemodialysis access failure ... Vascugel, a novel endothelial cell-based therapy and Pervasis, ... response following surgical interventions to create vascular access points ...
Cached Medicine Technology:Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis 2Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis 3Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis 4Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis 5
(Date:2/28/2015)... 28, 2015 The MCA Youth Empowerment ... into one platform and gears towards the goal for ... series of group talks in smaller groups will be ... Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, ... of Malaysian youths. , Young adults aged ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people to ... thinking. “The #1 block was lack of time ... Haman, who created the Thinkubator Innovation Studio in Chicago. ... they did not have enough time for innovative thinking ... innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops address ...
(Date:2/28/2015)... February 28, 2015 The Heart Fit ... a distributor of the machine. The Heart Fit Clinic ... license, like a franchise model. The goal is to ... reverse heart disease. To buy External Counterpulsation ... can help individuals through this process and achieve the ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
... 5, 2011) Autism Speaks, the world,s largest autism ... leader in educating parents and professionals about the early ... University,s Autism Institute today announced the launch of a ... Video Glossary , giving parents an important new tool ...
... States, the cost paid for statins (drugs to lower ... have private insurance is approximately 400 percent higher than ... Kingdom (U.K.). These findings, from the Boston University School ... the first results of a comprehensive comparison of prescription ...
... Jan. 5 (HealthDay News) -- Man,s beloved four-legged friends not only ... understand and anticipate the intentions of their people, researchers are reporting. ... who had direct eye contact with a person were more likely ... than if the person didn,t make direct eye contact with them. ...
... More than half of U.S. jails didn,t receive any vaccine ... flu, a new study says. Jail and prison inmates ... steady stream of new arrivals can introduce new types of ... for diseases to spread, researchers from the U.S. Centers for ...
... , THURSDAY, Jan. 5 (HealthDay News) -- Giving antibiotics ... reduces infection rates in newborns, according to a new study. ... common in high-income nations and should also be used in ... study author Dr. Karen Edmond, of the London School of ...
... the Twin Cities would create both opportunities and potential risks ... would pass through, according to a health impact assessment (HIA) ... coalition of 90 congregations of various faiths in the Minneapolis, ... possible through a grant by the Health Impact Project, which ...
Cached Medicine News:Health News:Autism Speaks, FSU and First Signs launch Autism Video Glossary treatment section 2Health News:Study finds statin costs 400 percent higher in US compared to UK 2Health News:Like Babies, Dogs Pick Up on People's Intent 2Health News:Like Babies, Dogs Pick Up on People's Intent 3Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Antibiotics in Pregnancy May Shield Newborns From Strep B 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 3
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
Medicine Products: